Ask about this productRelated genes to: FGFR2 antibody
- Gene:
- FGFR2 NIH gene
- Name:
- fibroblast growth factor receptor 2
- Previous symbol:
- KGFR, BEK, CFD1, JWS
- Synonyms:
- CEK3, TK14, TK25, ECT1, K-SAM, CD332
- Chromosome:
- 10q26.13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-05-09
- Date modifiied:
- 2019-04-23
Related products to: FGFR2 antibody
Related articles to: FGFR2 antibody
- Biliary tract cancer (BTC), encompassing intrahepatic and extrahepatic cholangiocarcinoma as well as gallbladder cancer, represents a heterogeneous group of malignancies characterized by an aggressive clinical course and poor prognosis. Systemic chemotherapy with gemcitabine plus cisplatin has remained the standard first-line treatment for more than a decade because most patients are diagnosed at an advanced or unresectable stage, but the associated survival benefit is limited. Recent therapeutic advances have been driven by the integration of immunotherapy and molecularly targeted approaches. Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinically meaningful activity, particularly in combination with cytotoxic chemotherapy, and are increasingly being incorporated into first-line treatment strategies for advanced BTC. Concurrently, comprehensive molecular profiling has revealed substantial genomic heterogeneity and identified actionable alterations, including fibroblast growth factor receptor 2 (FGFR2) fusions, isocitrate dehydrogenase 1 (IDH1) mutations, and human epidermal growth factor receptor 2 (HER2) amplification, enabling the development of precision targeted therapies for selected patient populations. Despite these advances, the therapeutic responses to immunotherapy and targeted agents remain highly variable, and robust predictive biomarkers have yet to be established. Accordingly, optimizing patient selection by integrating molecular and immunologic characteristics has become a critical objective for improving clinical outcomes. This review provides an overview of the recent progress in immunotherapy and targeted therapy for BTC, focusing on pivotal clinical trials, therapeutic efficacy, current limitations, and future perspectives for personalized treatment strategies. - Source: PubMed
Lee InhoYoon Seung Bae - Over the last decade, there has been substantial growth in our understanding of the molecular drivers for thyroid tumors with the advent of next generation sequencing. Importantly, these drivers correlate with histopathologic features and clinical behavior. Briefly, RAS/RAS-like alterations result in modest activation of the MAPK pathway and produce follicular-patterned neoplasms, including follicular adenomas and follicular carcinomas, as well as non-invasive follicular thyroid neoplasm with papillary-like nuclear features and follicular subtype of papillary thyroid carcinoma (PTC). In contrast, BRAF V600E and related alterations result in robust activation of the MAPK pathway and display a papillary architecture with well-developed PTC nuclear features, including classic PTC and its non-follicular subtypes. Interestingly, a subset of thyroid carcinomas activates the MAPK pathway to an intermediate degree, resulting in mRNA expression patterns overlapping between the BRAF V600E-like and RAS-like categories, including tumors with fusions involving NTRK1-3, ALK, and FGFR2, which often display PTC features. In contrast, oncocytic tumors exhibit mitochondrial mutations and chromosomal copy number changes. Finally, a small subset of non-oncocytic tumors exhibits non-MAPK mechanisms of neoplasia, including transcriptional dysregulation, epigenetic alterations, or rare structural variants. In each molecular category, secondary alterations can occur; most notably TERT promoter and TP53 mutations occur with increasing frequency in high-grade differentiated, poorly differentiated, and anaplastic thyroid carcinomas. This article will review the diagnostic, prognostic, and therapeutic significance of molecular alterations across the spectrum of follicular cell derived thyroid tumors and discuss strategies for investigating unusual molecular alterations encountered in clinical practice. - Source: PubMed
Publication date: 2026/04/16
Stark LaurenDueber Julie CAllison Derek B - - Source: PubMed
- Cholangiocarcinoma (CCA) is a molecularly heterogeneous malignancy of the biliary tract with rising global incidence and distinct geographic variations in oncogenic drivers. Despite India’s significant cancer burden, genomic data on CCA in Indian patients remain sparse, limiting the development of targeted therapies. - Source: PubMed
Publication date: 2026/04/20
Suryavanshi MoushumiOstwal VikasJavle MilindKumar ManojShetty OmshreePatil DarshanaSharma ShivaniLimaye SewantiPatel AmolSirohi BhawnaBahl AnkurRohtagi Nitesh - Exposure to fine particulate matter (PM.) is increasingly recognized as a breast cancer risk factor, yet its combined effect with genetic susceptibility is unclear. This study examined the effects of PM. and genetic variants ESR1 (Estrogen Receptor 1) rs2046210 and FGFR2 (Fibroblast Growth Factor Receptor 2) rs2981582 on breast cancer risk. - Source: PubMed
Publication date: 2026/04/17
Liaw Yi-ChingWu Chih-DaLiaw Yi-ChiaHsu Shu-YiChao Mu-RongHu Chiung-WenLiaw Yung-Po